Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth

I-S Park¹, S-W Kang², Y-J Shin², K-Y Chae², M-O Park², M-Y Kim³, DN Wheatley⁴ and B-H Min*,²

¹Department of Anatomy, College of Medicine, Inha University, Incheon 400-103, Korea; ²Department of Pharmacology and BK21 Program for Medical Sciences, College of Medicine, Korea University, Seoul 136-705, Korea; ³AngioLab, Inc., Taejon 302-735, Korea; ⁴Department of Cell Pathology, University of Aberdeen, MacRobert Building, 581 King Street, Aberdeen AB24 5UA, UK

Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.

British Journal of Cancer (2003) 89, 907 – 914. doi:10.1038/sj.bjc.6601181 www.bjcancer.com

Keywords: antiproliferative; antiangiogenic; arginine deiminase; arginine; NO; citrulline

Arginine deiminase (ADI; EC 3.5.3.6) catalyses the hydrolysis of L-arginine to L-citrulline and ammonia (Miyazaki et al., 1990). Enzyme purified from Mycoplasma arginini inhibits proliferation of a several types of human cancer cells (Gong et al., 2000; Kang et al., 2000). Primarily, it would appear through depletion of arginine, because supplementation of the medium with a plentiful supply of arginine generally restores cell proliferation (Komada et al., 1997; Kang et al., 2000). In addition, ADI displays an antitumour activity in vivo, with seemingly minimal side effects (Takaku et al., 1992), and is said to inhibit proliferation of human leukaemia cells more potently than asparaginase (Gong et al., 2000), which is the only amino-acid-degrading enzyme regularly used in cancer chemotherapy. Nitric oxide (NO) modulates the activity of vascular endothelial growth factor, basic fibroblast growth factor, and matrix metalloproteinases during angiogenesis (Papapetropoulos et al., 1997; Sasaki et al., 1998), although there are conflicting views (Pipili-Synetos et al., 1994; Raychaudhury et al., 1996; Phillips et al., 2001).

Arginase can also regulate NO level because it is synthesized from L-arginine in a concentration-dependent manner (Gotoh and Mori, 1999). In fact, at least three enzymes destroy arginine. The second enzyme is arginine decarboxylase (Philip et al., 2003), and the third is ADI, which we recently showed to have the ability to deplete plasma arginine and suppress LPS-induced NO production, suggesting a potential inhibitory role of ADI in NO-mediated angiogenesis (Noh et al., 2002; Thomas et al., 2002). Wilm et al. (1996) purified a protein that strongly inhibited proliferation of vascular endothelial cells, later identified as ADI from Mycoplasma. Furthermore, in vitro antiangiogenic activity of ADI was recently reported to inhibit migration and microvessel tube formation in human umbilical vein endothelial cell cultures (Beloussow et al., 2002). Thus, ADI seems to inhibit tumour growth not only by exhausting the supplies of a vital nutrient (arginine), but also by its antiangiogenic activity via suppression of NO generation. We have therefore examined whether recombinant ADI expressed in Escherichia coli inhibits in vivo angiogenesis, using several experimental models. We also report on its effects on tumour cell growth in the presence or absence of nitric oxide.

MATERIALS AND METHODS

Materials

Cell culture plates were purchased from Corning Costar (Cambridge, MA, USA). Basic fibroblast growth factor (bFGF), endothelial cell growth supplement, heparin, and Drabkin reagent kit 525 were from Sigma (St Louis, MO, USA). M199, isopropyl β-D-thiogalactopyranoside (IPTG) and fetal bovine serum (FBS) were from Life Technologies (Grand Island, NY, USA). Matrigel was from BD Biosciences (Bedford, MA, USA), and Sephacryl S-100, DEAE- and arginine-Sepharose resins were from Amersham Pharmacia Biotechnology (Piscataway, NJ, USA).

Purification of recombinant ADI

The ADI gene was cloned by polymerase chain reaction (PCR) using M. arginini genomic DNA. The tryptophan codon TGA in
the coding region that corresponds to a stop codon in E. coli was changed to TGG by site-directed mutagenesis, using the overlap extension PCR method (Ho et al, 1989). The mutated ADI gene was cloned into a PET32a (+) expression vector (designated PET32a-ADI) and transformed into E. coli strain BL21. Recombinant ADI overexpressed as inclusion bodies was denatured with 6 M guanidine HCl, refolded in 100 mM potassium phosphate buffer (pH 7.4), and purified by DEAE- and arginine-Sepharose column chromatography (Kang et al, 2000).

Cell culture

CHO, HeLa, and neonatal foreskin fibroblasts (9th passage of a primary cell culture) cells were grown as stocks in RPMI 1640 with 10% fetal calf serum and antibiotics. They were transferred to 24-well plates for growth studies, with the enzyme being incubated in arginine-deficient RPMI 1640 to which 5% dialysed serum and the appropriate test substance was added. Amino-acid additions were made at 400 μM. Negative controls were given no arginine supplementation, but cultures to receive ADI were replete with arginine. The ADI was normalised in its activities such that its IC50 was set at a level of 0.1 U ml−1, due to changes in specific activity of the enzyme during shipments to Scotland. The specific activities of batches 1 and 2 ADI used were originally 58.3 and 46.4 U mg−1 protein, respectively. Effects of cells were seen at 0.1 – 1 U ml−1. Better data were obtained with 2 U ml−1, corresponding to higher ID50 in the range 0.1 – 1.0 ng ml−1 following normalisation, and agrees well with the data of other groups (e.g. Miyazaki et al, 1990; Gong et al, 2000). Pegylation of ADI was not carried out for this in vitro work. Sodium nitroprusside (Sigma, Poole, UK) was added to the culture medium at a final concentration of between 10 and 250 μM, as appropriate.

Avoidance of mycoplasmal contamination. Essential to this study has been the regular checking of cultures for mycoplasma contamination. The most devastating effect on cell cultures can be seen with arginine deiminase released from M. arginini as a contaminant. Using the Roche Mycoplasma Detection Kit for four prevalent species of Mycoplasma that includes M. arginini, cultures were tested before experimentation, according to the manufacturer’s instructions. The only cell line that occasioned positive M. arginini results was HeLa, and fresh uncontaminated cultures were selected for the present work (see Figure 7). However, we also used a supernatant preparation from a pure culture of M. arginini provided by Dr Robin Nicholas (Veterinary Laboratories Agency, Weybridge, UK) for comparison with recombinant ADI from E. coli.

Growth was measured daily by electronic (Coulter) counting of the cells in three wells per data point. Averages were plotted with one standard deviation of the mean shown in each case. Where bar lines do not appear, they will be within the symbols used on the graphs.

Tube formation assay

Human umbilical vein endothelial cells (HUVECs) were prepared from freshly delivered cords (Jaffe et al, 1973) and confirmed by immunocytochemical staining for Factor VIII. The cells were cultured in 25 cm2 flasks in M199 media supplemented with 10% FBS, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, 50 μg ml−1 endothelial cell growth supplement, and 50 μg ml−1 heparin in a 37°C incubator with humidified atmosphere containing 5% CO2. The cells between passages 3 and 5 were used for in vitro experiments. Capillary-like tube formation assay was performed as described previously (Grant et al, 1992), but with the following modifications. The 48-well plates were coated with 200 μl Matrigel (10 mg ml−1) by incubating at 37°C for 1 h. Human umbilical vein endothelial cells were suspended in M199 media supplemented with 10% FBS, and plated onto a layer of Matrigel at a density of 4 × 104 cells well−1 with or without ADI. The plates were incubated for a further 18 h at 37°C, and capillary-like tube formation was observed microscopically, their area of being measured using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA).

CAM assay

Fertilised chicken eggs were incubated at 37°C in a humidified incubator. On the third day of incubation, 2 ml of albumin was aspirated from the eggs with an 18-gauge hypodermic needle to detach the developing CAM from the shell. On the fourth day, the shell was punched out to make a window and sealed with a cellophane tape. Thermannox coverslips (Nunc, Naperville, IL, USA) coated with or without 0.046 U ADI were applied to the CAM surface through the windows for 2 days. After injection of an appropriate volume of 10% fat emulsion (intralipose) into the chorioallantois, angiogenesis in CAM was observed under a microscope, with >20 eggs being used for each assay.

In vivo Matrigel plug assay

Male C57BL/6 mice (7 weeks old) were supplied from Daehan Biolink Co. (Seoul, South Korea). Matrigel plug assay in mice was performed as described previously (Passaniti et al, 1992). Briefly, 0.4 ml of Matrigel containing 0.46 U ml−1 ADI, 50 ng ml−1 bFGF, and 60 U ml−1 heparin were injected subcutaneously near the abdominal midline of the mice using a 25-gauge needle. Control animals were subjected to subcutaneous injection of Matrigel mixture without ADI. Where heparin and bFGF were used, these were added along with the Matrigen inoculation. After injection, the Matrigel rapidly formed a solid gel at the site of injection. Plugs were separated from the abdominal wall after 5 days and fixed with 3.7% formaldehyde in phosphate-buffered saline. The formalin-fixed Matrigel samples were embedded in paraffin and examined with Masson-trichrome stain. To evaluate new blood vessel formation, haemoglobin content was measured with a Drabkin reagent kit 525. The concentration of haemoglobin was calculated from a known amount of haemoglobin assayed in parallel. The experiment was repeated twice with five mice in each group.

RESULTS

Expression and purification of recombinant ADI

Recombinant ADI gene was expressed in E. coli as a thioredoxin fusion protein with His-tag and S-tag, using a PET32a (+) expression vector. Thioredoxin – ADI fusion protein was accumulated in the cytoplasm as inclusion bodies and its molecular weight was estimated at 64 kDa (Figure 1A; this is included here to show the authenticity of the batches of enzyme prepared for the present work). However, the fusion protein tended to be self-degrading during the process of denaturation and refolding for purification. Although the precise cleavage site of self-digestion in the linker region was not determined, enough enzyme activity was retained to hydrolyse arginine. However, this gave a much lower specific activity than for recombinant arginase (Philip et al, 2003). Our recombinant ADI was estimated at 49 kDa on SDS–PAGE and 98 kDa by Sephacryl S-100 gel filtration (Figure 1A and B), indicating the same dimeric structure as native ADI purified from M. arginini (Takaku et al, 1992). After DEAE-Sepharose and arginine-affinity column chromatography, ∼ 5 mg active ADI was purified from 11 of culture.

Inhibition of capillary-like tube formation of HUVECs by ADI

To examine the effect of ADI on tube formation by vascular endothelial cells, HUVECs were plated on the Matrigel-coated
Inhibition of angiogenesis by ADI in vitro

To determine the in vitro antiangiogenic effect of ADI, CAM and Matrigel plug assays were carried out. At 0.046 U ml⁻¹, ADI significantly inhibited chick embryonic angiogenesis, producing an avascular zone beneath the disk in 88% of the ADI-treated group, whereas control CAMs treated with saline showed no disturbance of angiogenesis (Figure 4). In addition, ADI inhibition was quantitatively estimated using the in vivo mouse Matrigel plug assay. After 5 days of implantation, the control – Matrigel plugs containing bFGF and heparin without ADI appeared dark red in colour due to massive formation of blood vessels. Matrigel plugs treated with 0.46 U ml⁻¹ ADI in combination with bFGF and heparin remained pale, indicating no blood vessel formation (Figure 5A). Haemoglobin content in the Matrigel plugs was taken as a measure of vasculature formation; the content in control Matrigel without ADI was 75.2 ± 13.8 g dl⁻¹ (n = 5), whereas Matrigel with 0.46 U ml⁻¹ ADI was 2.5 ± 0.1 g dl⁻¹ (n = 7, Figure 5B), indicating that ADI inhibited growth factor-induced angiogenesis in this model by ~97%.

In experiments testing the effect of the spontaneous nitric oxide generator, sodium nitroprusside, both HUVEC and fibroblasts in angiogenesis co-culture (Bishop et al, 2000) tolerated the upper range of our treatment very well (10–500 µM), and there was no obvious effect of tubule formation throughout their period of development (14 days) in the co-culture system, whether or not sodium nitroprusside was added to the medium being replaced every other day (data not shown).
Inhibition of tumour cell growth by ADI

We reasoned that if inhibition of tumour cell growth by ADI in vitro was primarily and largely due to depletion of arginine, the responses of two of the three carefully chosen cell lines would be decidedly different (Wheatley and Campbell, 2003). We have tested ADI on many cells lines and found that it inhibits growth and/or kills cells as effectively as arginase treatment (Scott et al, 2000), but we have confined our experiments here to these two because they represent the ends of a spectrum of the ability of cells to utilise citrulline. Thus, ADI should be highly effective against cells that are incapable of metabolising citrulline in lieu of arginine, the selection therefore being the CHO cell line. However, whether citrulline is produced by ADI or exogenous citrulline is added to the culture medium of cells that can metabolise it to arginine, ADI should be less effective. HeLa cells can metabolise exogenous citrulline, although a concentration ~2 times greater than arginine is needed to sustain a comparable growth rate (Philip et al, 2003). Data from a comparative experiment with ADI clearly show its greater damaging action on CHO than HeLa cells (Figure 6). The sensitivity of CHO to the ADI in Figure 7 includes curves for cultures set up at time zero in arginine-free medium, to which arginine was either added at the same time as the enzyme at two equivalent concentrations, which made no difference to the resulting depression of growth (therefore data not shown; see Discussion). N.B. At 100–250 μM, a few cells were damaged in the early treatment of controls, but there was no increased (synergistic or additive) effect of ADI treatment.

DISCUSSION

Antiangiogenic effects

Recombinant ADI from E. coli inhibits angiogenesis in two different experimental systems. Arginine deiminase suppressed in vitro capillary-like tube formation of vascular endothelial cells and in vivo neovascularisation in the CAM and the Matrigel plug assays in the mouse. This microbial enzyme, ADI, specifically hydrolyses arginine to citrulline, leading to depletion of an essential amino acid that is utilised not only for protein synthesis, but also is a substrate for NO, polyamine, proline, and glutamate production in mammals (Wu and Morris, 1998). Deprivation of extracellular arginine by ADI treatment inevitably disrupts a number of biochemical pathways, including some intracellular regulatory signals for endothelial cell growth. Although an
antiangiogenic activity of NO has been reported (Raychaudhury et al., 1996; Philip et al., 2001), several investigators showed a positive association of NO level with angiogenic activity (Papapetropoulos et al., 1997; Murohara et al., 1998). Interestingly, overexpression of arginase, another arginine-degrading enzyme, markedly inhibits NO synthesis and enhances polyamine production in endothelial cells by modulating intracellular arginine availability (Li et al., 2001). Thus, it can be assumed that the antiangiogenic effects of ADI are associated with NO suppression resulting from depletion of arginine. Inhibition of capillary-like tube formation of vascular endothelial cells by ADI treatment is more likely to be due to the depletion of arginine, since exogenous arginine supplementation reversed its inhibitory effects. We found no evidence that the lack of NO production as a consequence of arginine deprivation has any significant effect of the angiogenic process in the presence or absence of ADI.

In addition to NO suppression per se being not relevant in this context, arginine depletion by ADI treatment would alter levels of polyamines, proline, and glutamate. As polyamines are essential for proliferation of endothelial cells (Morrison et al., 1995), their decreased synthesis may also affect angiogenesis. In fact, α-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, a rate-limiting enzyme in the polyamine biosynthesis, inhibited proliferation of HUVECs (Takahashi et al., 2000). Thus, decreased polyamine synthesis due to ADI treatment will no doubt exacerbate the antiangiogenic action.

Antitumour action

With regard to the suppression of tumour cell growth by ADI, our findings clearly indicate that cells behave the same way whether or not NO is present, unlike endothelial cells. The inhibitory action of the enzyme will be principally due to a drastic limitation of arginine that accounts for CHO and HeLa cells being arrested in growth, and both of these lines undergo considerable death because malignant cells fail to reach quiescence (Scott et al., 2000). However, this does not necessarily explain the damaging as...
Experimental Therapeutics

Antitumour effects of arginine deiminase
I-S Park et al

**Figure 6** Comparison of the effect of ADI on CHO and HeLa cell growth. CHO and HeLa cells were treated with comparable levels of ADI (0.05 and 0.1 U ml⁻¹) and the data giving cell number relative to the start (50,000 cells per well) are recorded as means of triplicate sample after 1, 3, and 5 days. In both cases, the CHO cells were more vulnerable than HeLa cells (HeLa cultures have stippled bars, CHO are plain).

**Figure 7** Dose–response curves for ADI on CHO cells with (solid lines) and without arginine (broken lines). Effect of increasing concentrations of ADI from 0.01 to 1 U ml⁻¹ (see inset box) on CHO cells from an inoculum of 50,000 cells per well (100%), and expressed daily as a percentage relative to the control (O). The dashed curve (- - -) gives data for a culture in which 0.1 U ml⁻¹ ADI were added but without 400 μM arginine being present. (Note that this curve is much less steep and some of the cells persist and are viable at the end of the experiment (5 days), whereas those given arginine and enzyme were dead within 3 days.)

opposed to arresting action of ADI on normal fibroblasts (Figure 8). Furthermore, we see the damaging action of ADI being manifest here not so much in the absence of arginine (in the negative controls), as when it has acted upon arginine from the start of the incubation. Although we have not proved that the release of nascent NH₃ (not ammonium ions) as the by-product of arginine degradation by ADI is responsible, this interpretation seems reasonable. When we consider the effect on CHO and HeLa cells (Figures 6–8), it is noteworthy that tumour cells are particularly affected at critical ADI concentrations, once again presumably through the release of nascent NH₃. When arginine is present rather than absent and ADI is added critically at ~0.2 to 0.4 U ml⁻¹, both elements are clearly involved, and thus it is not an ‘either/or’ situation, but one where both apply, resulting in the more devastating effect of ADI in the presence of arginine. This is in good agreement with the data of Gong et al (2000) and others reporting massive cell death with ADI (Komada et al, 1997), although not entirely with their interpretation.

**Native ADI**

We also checked that the purified enzyme prepared from *E. coli* possessed all the characteristics of authentic ADI originating from a pure strain of *M. arginini* (Figure 8). The evidence is a salutary reminder that cultures of cells need to be regularly checked for *M. arginini* because the ADI released from these organisms in considerable quantities devastates cultures of both normal and malignant phenotypes.

It is most unlikely that NO being produced through the action of other enzymes on arginine (NO synthase) plays a role in tumour cell death. Sodium nitroprusside at concentrations that should release very considerably greater amounts of NO into a closed culture system would not be expected to show toxicity until ~100 μM, and it is already known that some cell types such as rat lung epithelial cells (Bundschuh et al, 1995) tolerate 2.6 mM sodium nitroprusside. We found some occasional cell damage soon after treatment at 100 μM and a little more at 250 μM, but this was neither additive nor synergistic in nature. The absence of NO would not in any way have been responsible for helping cells to survive the effect of arginine deprivation induced by ADI.

Previously, ADI was reported to have in vivo antitumour activity (Takaku et al, 1992), especially in leukaemia. Gong et al (2000) claimed it was more effective than 1-asparaginase, but did not to take into account the widely disparate specific activities of the two...
enzymes (Wheatley and Campbell, 2002), comparing them only on a mass per volume basis. Arginine is one of the essential nutrients for mammalian cells and the first amino acid depleted by cell metabolism in culture (Wheatley et al., 2000). The rapid depletion of arginine may be partly due to the fact that arginine is less efficiently recycled (especially residues recovered from catabolised proteins) by cultured cells than other amino acids, but the kinetics of this recycling have yet to be determined in animals where tumours have been inhibited by ADI. The reutilisation of citrulline following ADI action remains a worrying aspect of its efficacy, but will always depend on an intact urea cycle (lacking in many tumour cell types, Wheatley and Campbell, 2003).

General conclusions

Upon deprivation of arginine, normal diploid fibroblasts having stringent check points of cell cycle can survive for several days in a quiescent state (G0) after exiting from cell cycle, whereas tumour cells lacking stringent regulatory cell cycle checkpoint fail to enter quiescence and continue to divide until cell death intervenes through some form of imbalance and/or apoptosis (Scott et al., 2000; Wheatley et al., 2000). Thus, deprivation of arginine by ADI could induce detrimental pleiotypic responses and lead to prompt tumour cell death by disrupting the biochemical pathways of the cell cycle. In addition to its antiproliferative effect on tumour growth, we demonstrated that ADI suppressed angiogenesis by inhibiting both tube formation of endothelial cells and neovascularisation in CAM and Matrigel plug assay. Since the latter does not require cell proliferation, the action of arginine degrading enzyme may play other roles than simply reducing the availability of arginine as a precursor in these and other pathways that have not already been mentioned. Solid tumours could not proliferate continuously without recruiting a blood supply by angiogenesis (Folkman et al., 1995). These results suggest that ADI could synergistically inhibit in vivo solid tumour growth by the combined action of antiproliferative activity through the depletion of arginine as a nutrient and its own antiangiogenic activity. However, it is also clear that the different strands of this complex process need to be teased out and subjected to a more thorough analysis, especially the rate of citrulline recycling.

ACKNOWLEDGEMENTS

Kang and the first author made equal contributions to the work. This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (HMP-00-B-20700-0021 to B-H Min and HMP-06-VN-01-215000-0007 to M-Y Kim). We are grateful for the pure cultures of M. arginini. DNW thank Miss Jane Sarginson and Miss Elaine Campbell for assistance with cell culturing.

REFERENCES

Beloussow K, Wang L, Wu J, Ann D, Shen WC (2002) Recombinant arginase deiminase as a potential anti-angiogenic agent. Cancer Lett 183: 155 – 162
Bishop E, Bell GD, Bloom S, Broome J, Hendry NFK, Wheatley DN (2000) An in vitro model for angiogenesis: basic features. Angiogenesis 3: 335 – 344
Bundschuh DS, Uhlig S, Leist M, Sauer A, Wendel A (1995) Isolation and characterization of rat primary lung cells. In Vitro Cell Dev Biol Anim 31: 684 – 691
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27 – 31
Gong H, Zoller F, von Recklinghausen G, Havers W, Schweigerer L (2000) Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14: 826 – 829
Gotoh T, Mori M (1999) Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. J Cell Biol 144: 427 – 434
Grant DS, Kinsella JL, Fridman R, Auerbach R, Piascik BA, Yamada Y, Zain M, Kleinman HK (1992) Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 153: 614 – 625
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51 – 59
Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human articular chondrocytes. J Cell Physiol 82: 129 – 141
Li H, Meininger CJ, Hawker JR, Haynes TE, Kepka-Lenthart D, Mistry SK, Morris Jr SM, Wu G (2001) Regulatory role of arginine I and II in nitric oxide, polyamine, and proline synthesis in endothelial cells. Am J Physiol Endocrinol Metab 280: E75 – E82
Miyazaki K, Takaku H, Umeda M, Fujita T, Huang WD, Kimura T, Yamashita J, Horio T (1990) Potent growth inhibition of human tumour cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 50: 4522 – 4527
Morrison RF, Seidel ER (1995) Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovasc Res 29: 841 – 847
Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Synes JF, Fishman MC, Huang PL, Isner JM (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567 – 2578
Noh EJ, Kang SW, Shin YJ, Kim DC, Park IS, Kim MY, Chung BG, Min BH (2002) Characterization of Mycoplasma arginini deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis. Mol Cells 13: 137 – 143
Papapetropoulos A, Garcia-Cardenas G, Madri JA, Sessa WC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131 – 3139
Passanti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67: 519 – 528
Philip R, Campbell E, Wheatley DN (2003) Arginine deprivation, growth inhibition and tumour cell death. 2. Enzymatic degradation of arginine in cultures of normal and malignant cells. Br J Cancer 88: 613 – 623
Phillips PG, Birnby LM, Narendran A, Milanovich WL (2001) Nitric oxide modulates capillary formation at the endothelial cell–tumour cell interface. Am J Physiol Lung Cell Mol Physiol 281: L278 – L290
Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Andriopoulou P, Peristeris P, Maragoudakis ME (1994) Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 111: 894 – 902
RayChaudhury A, Frischer H, Malik AB (1996) Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. J Cell Biochem 63: 125 – 134
Sasaki K, Hattori T, Fujisawa T, Takahashi K, Iinoe H, Takigawa M (1998) Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem (Tokyo) 123: 431 – 439
Scott L, Lamb J, Smith S, Wheatley DN (2000) Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 83: 800 – 810
Takahashi Y, Mai M, Nishioka K (2000) -difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumour growth
and metastasis in a human gastric cancer model. *Int J Cancer* 85: 243–247
Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K (1992) *In vivo* anti-tumour activity of arginine deiminase purified from *Mycoplasma arginini*. *Int J Cancer* 51: 244–249
Thomas JB, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA (2002) Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin. *Biochem J* 363: 581–587
Wheatley DN, Campbell E (2002) Arginine catabolism, liver extracts and cancer. *Pathol Oncol Res* 8: 18–25

Wheatley DN, Campbell E (2003) Arginine deprivation, growth inhibition and tumour cell death. 3. Deficient utilisation of citrulline by malignant cells. *Br J Cancer* (in press)
Wheatley DN, Scott L, Lamb J, Smith S (2000) Single amino acid (arginine) restriction: growth and death of cultured HeLa and human diploid fibroblasts. *Cell Physiol Biochem* 10: 37–55
Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M (1996) Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. *Nature* 379: 466–469
Wu G, Morris Jr SM (1998) Arginine metabolism: nitric oxide and beyond. *Biochem J* 336: 1–17

Wheatley DN, Campbell E (2003) Arginine deprivation, growth inhibition and tumour cell death. 3. Deficient utilisation of citrulline by malignant cells. *Br J Cancer* (in press)